<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31670">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01750918</url>
  </required_header>
  <id_info>
    <org_study_id>116833</org_study_id>
    <nct_id>NCT01750918</nct_id>
  </id_info>
  <brief_title>BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer</brief_title>
  <official_title>An Open-Label, Three-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212, BRAF Inhibitor GSK2118436 and the Anti-EGFR Antibody Panitumumab in Combination in Subjects With BRAF-mutation V600E or V600K Positive Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, three-part Phase 1/2 study to investigate the safety,
      pharmacokinetics, pharmacodynamics and clinical activity of trametinib (GSK1120212) and
      dabrafenib (GSK2118436) when administered in combination with the anti-EGFR antibody
      panitumumab in subjects with BRAF-mutation V600E or V600K positive colorectal cancer (CRC).
      Part 1 of the study will consist of dose-escalation cohorts Part 2 of the study will consist
      of expansion cohorts to investigate safety and clinical activity, and Part 3 of the study
      will be a randomized Phase II study comparing both the dabrafenib/panitumumab and
      dabrafenib/trametinib/panitumumab combinations to a chemotherapy comparator with respect to
      safety and clinical activity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, three-part Phase 1/2 study to investigate the safety,
      pharmacokinetics, pharmacodynamics and clinical activity of trametinib (GSK1120212) and
      dabrafenib (GSK2118436) when administered in combination with the anti-EGFR antibody
      panitumumab in subjects with BRAF-mutation V600E or V600K positive colorectal cancer (CRC).
      Part 1 of the study will consist of dose-escalation cohorts, following a 3 + 3 enrollment
      scheme. The maximum tolerated dose (MTD)/Recommended Phase 2 Regimen (RP2R) of dabrafenib
      plus panitumumab will be defined first in Part 1. Upon definition of a tolerable dose of
      dabrafenib plus panitumumab, trametinib will be added to the combination and subsequent
      cohorts will dose with all three drugs in combination. Part 2 of the study will consist of
      expansion cohorts to enroll subjects with BRAF-mutation V600E or V600K positive CRC, and
      investigate safety and clinical activity of dabrafenib in combination with panitumumab and
      trametinib plus dabrafenib in combination with panitumumab. For each combination
      (dabrafenib/panitumumab and dabrafenib/trametinib/panitumumab), the optimal safe and
      tolerable dose combinations defined in Part 1 will be brought forward into Part 2. Based on
      the safety and tolerability of these combinations, these doses may be modified during Part 2
      of the study. Part 3 of the study will be a randomized Phase II study comparing dosing with
      dabrafenib in combination with panitumumab and trametinib plus dabrafenib in combination
      with panitumumab as compared to a chemotherapy comparator. Subjects will be assigned to one
      of three treatment groups in a randomized fashion to compare safety and clinical activity:
      1) dabrafenib plus panitumumab, 2) dabrafenib plus trametinib plus panitumumab, or 3)
      chemotherapy comparator. Dose levels for dabrafenib, trametinib, and panitumumab in Part 3
      will be chosen based on emerging PK, PD, and tolerability data from Part 1 and Part 2. In
      the event that the benefit/risk ratio for either of the two experimental combinations is not
      sufficiently positive (either due to excessive toxicity or clearly inferior efficacy), one
      of the arms may be excluded from Part 3 of the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Dose-limiting toxicities (DLTs)</measure>
    <time_frame>one year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Patients will be monitored weekly for changes from baseline in vital signs, electrocardiograms (ECGs), laboratory blood tests and for any adverse effects over the first 28 days of dosing. In the continuation period, patients will be monitored every 4 weeks for changes from baseline in vital signs, ECGs, laboratory blood tests and for any adverse effects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics of dabrafenib, trametinib and panitumumab in combination dosing.</measure>
    <time_frame>up to and including Week 20</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serial blood samples will be collected predose and post-dose on Day 1, Day 15 and pre-dose on Day 21 in the first 28 days of dosing. In the continuation period, blood samples will be collected every 4 weeks up to and including Week 20 on study. Pharmacokinetic paramenters will include maximum observed concentration, time of occurrence of maximum observed concentration, and area under the concentration-time curve and trough concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate (complete response + partial response)</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tumors will be assessed using investigator read computed tomography (CT) or magnetic resonance imaging (MRI) at baseline, then every 6 weeks until Week 24 on study, then every 8 weeks, and again at follow-up for patients who discontinue study medication for any reason other than progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression -free survival (PFS)</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tumors will be assessed using investigator read computed tomography (CT) or magnetic resonance imaging (MRI) at baseline, then every 6 weeks until Week 24 on study, then every 8 weeks, and again at follow-up for patients who discontinue study medication for any reason other than progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tumors will be assessed using investigator read computed tomography (CT) or magnetic resonance imaging (MRI) at baseline, then every 6 weeks until Week 24 on study, then every 8 weeks, and again at follow-up for patients who discontinue study medication for any reason other than progression or death.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Doublet: Dabrafenib plus Panitumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dabrafenib plus panitumumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triplet: Dabrafenib plus Trametinib plus Panitumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dabrafenib plus trametinib plus panitumumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5-fluorouracil-based chemotherapy comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5-fluorouracil-based chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 1 Cohort 1: Dabrafenib plus Panitumumab</intervention_name>
    <description>Doublet</description>
    <arm_group_label>Doublet: Dabrafenib plus Panitumumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 1 Cohort 2: Dabrafenib plus Trametinib plus Panitumumab</intervention_name>
    <description>Triplet</description>
    <arm_group_label>Triplet: Dabrafenib plus Trametinib plus Panitumumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 1 Cohort 3A: Dabrafenib plus Trametinib plus Panitumumab</intervention_name>
    <description>Triplet</description>
    <arm_group_label>Triplet: Dabrafenib plus Trametinib plus Panitumumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 1 Cohort 3B: Dabrafenib plus Trametinib plus Panitumumab</intervention_name>
    <description>Triplet</description>
    <arm_group_label>Triplet: Dabrafenib plus Trametinib plus Panitumumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 1 Cohort 4: Dabrafenib plus Trametinib plus Panitumumab</intervention_name>
    <description>Triplet</description>
    <arm_group_label>Triplet: Dabrafenib plus Trametinib plus Panitumumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 2 Cohort 1: Dabrafenib plus Panitumumab</intervention_name>
    <description>Doublet</description>
    <arm_group_label>Doublet: Dabrafenib plus Panitumumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 2 Cohort 2: Dabrafenib plus Trametinib plus Panitumumab</intervention_name>
    <description>Triplet</description>
    <arm_group_label>Triplet: Dabrafenib plus Trametinib plus Panitumumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 3 Cohort 1: Dabrafenib plus Panitumumab</intervention_name>
    <description>Doublet</description>
    <arm_group_label>Doublet: Dabrafenib plus Panitumumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 3 Cohort 2: Dabrafenib plus Trametinib plus Panitumumab</intervention_name>
    <description>Triplet</description>
    <arm_group_label>Triplet: Dabrafenib plus Trametinib plus Panitumumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 3 Cohort 3: 5-fluorouracil-based chemotherapy</intervention_name>
    <description>chemotherapy comparator</description>
    <arm_group_label>5-fluorouracil-based chemotherapy comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

          -  Written informed consent provided.

          -  At least 18 years of age or older.

          -  Able to swallow and retain oral medication.

          -  No clinically significant gastrointestinal (GI) abnormalities that may alter
             absorption such as malabsorption syndrome or major resection of the stomach and/or
             bowels.

          -  Confirmed diagnosis of advanced or metastatic BRAF V600E or V600K mutation positive
             colorectal cancer (CRC).

          -  Archival tissue is required; if archival tissue is not available or found to not
             contain tumor tissue, a fresh biopsy is required.

          -  Measurable disease per RECIST version 1.1.

          -  Performance Status Score of 0 or 1 according to the Eastern Cooperative Oncology
             Group scale.

          -  Men must have either:

        had a prior vasectomy, or agree to use one of the contraception methods listed in the
        protocol from the time of the first dose of study drug(s) and until 6 months after the
        last dose of panitumumab, or 16 weeks following the last dose of dabrafenib or trametinib,
        based on the life cycle of sperm.

          -  Female subjects are eligible if:

        Non-childbearing potential defined as:

        pre-menopausal females with a documented tubal ligation or hysterectomy; or
        post-menopausal female defined as 12 months of spontaneous amenorrhea to be verified with
        a follicle-stimulating hormone (FSH) level &gt;40MIU/mL and estradiol level &lt;40pg/mL.

        Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will
        be required to use one of the contraception methods in the protocol if they wish to
        continue their HRT during the study.  Otherwise, they must discontinue HRT to allow
        confirmation of post-menopausal status prior to study enrollment.  For most forms of HRT,
        at least 2 to 4 weeks will elapse between the cessation of therapy and the blood draw;
        this interval depends on the type and dosage of HRT. Following confirmation of
        post-menopausal status, they can resume use of HRT during the study without use of a
        contraceptive method.

        Child-bearing potential and agrees to use one of the contraceptive methods listed in the
        protocol for an appropriate period of time as determined by the product label and
        applicable IBs) prior to the start of dosing to sufficiently minimize risk of pregnancy at
        that point.

          -  Female subjects must agree to use contraception from the time of the first dose of
             study drug(s) until 60 days after the last dose of any study drug. Note: oral
             contraceptives are not reliable due to potential drug-drug interactions.

          -  Women of childbearing potential must have had a negative serum pregnancy test within
             7 days prior to the first dose of study drug(s).

          -  Adequate organ system functions, including:

        absolute neutrophil count greater than or equal to 1.2X10^9/L, hemoglobin greater than or
        equal to 9 g/dL or 5.6 mmol/L, platelets greater than or equal to75 Ã— 10^9/L, Prothrombin
        Time / International Normalized Ratio (PT/INR) and Partial Thromboplastin Time (PTT) less
        than or equal to 1.5Xupper limit of normal (ULN) serum magnesium greater than or equal to
        the lower limit of normal (LLN) albumin greater than or equal to 2.5 g/dL or 25 g/L, total
        bilirubin less than or equal to 1.5XULN, and AST and ALT less than or equal to 2.5XULN
        creatinine less than or equal to 1.5XULN or calculated creatinine clearance greater than
        or equal to 50mL/min left ventricular ejection fraction (LVEF) greater than or equal to
        the LLN by echocardiography (ECHO) or multigated acquisition scan (MUGA).

        EXCLUSION CRITERIA

          -  History of prior malignancy, other than colorectal cancer.

          -  Any serious and/or unstable pre-existing medical, psychiatric disorder or other
             conditions that could interfere with subject's safety, obtaining informed consent or
             compliance to the study procedures.

          -  Current active liver or biliary disease (with the exception of Gilbert's syndrome or
             asymptomatic gallstones, liver metastases or otherwise stable chronic liver disease
             per investigator's assessment).

          -  History of sensitivity to heparin or heparin-induced thrombocytopenia.

          -  Currently receiving cancer therapy (chemotherapy, radiation therapy, immunotherapy or
             biologic therapy), as described in the protocol.

          -  Prior exposure to BRAF or MEK inhibitors.

          -  Prior exposure to EGFR inhibitors, including anti-EGFR antibodies or EGFR (for
             patients enrolling in Part 2 ONLY)

          -  Known presence of KRAS-mutation based on previous KRAS-testing.

          -  Received an investigational or approved anti-cancer drug within 4 weeks, or within 5
             half-lives (whichever is shorter) of the first dose of study drug(s). At least 14
             days must have passed between the last dose of prior investigational agent and the
             first dose of study drug(s).

          -  Current use of a prohibited medication or requirement to dose with any of these
             medications during treatment with study drug(s).

          -  Known human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C infection.
             Subjects who have evidence of clearance of Hepatitis B or Hepatitis C infection can
             be enrolled with approval of the GSK Medical Monitor.

          -  Current use of therapeutic warfarin.  Therapeutic dosing of warfarin is defined as
             resulting in an INR greater than 1.3.  Low molecular weight heparin (LMWH) is
             permitted provided that the subject's PT and PTT meet entry criteria. Subjects
             requiring therapeutic levels of LMWH must receive approval from GSK Medical Monitor
             and must be monitored appropriately as clinically indicated.

          -  Any major surgery, radiotherapy or immunotherapy within the 4 weeks prior to first
             dose of study drug(s). Limited radiotherapy with in the 2 weeks prior to first dose
             of study drug(s).

          -  Chemotherapy regimens with delayed toxicity within the 3 weeks prior to first dose of
             study drug(s).  Chemotherapy regimens given continuously or on a weekly basis with
             limited potential for delayed toxicity within 2 weeks prior to first dose of study
             drug(s).

          -  Unresolved toxicity greater than National Cancer Institute Common Terminology
             Criteria for Adverse Events (NCI-CTCAE; version 4) Grade 1 from previous anti-cancer
             therapy, with the exception of Grade 2 alopecia, Grade 2 neuropathy, or laboratory
             values that are allowed per inclusion criteria.

          -  History of retinal vein occlusion (RVO) or central serous retinopathy (CSR),
             predisposing factors to RVO or CSR (e.g., uncontrolled glaucoma or ocular
             hypertension, uncontrolled systemic disease such as hypertension, diabetes mellitus,
             or a history of hyperviscosity or hypercoagulability syndromes).

          -  Visible retinal pathology as assessed by ophthalmic examination that is considered a
             risk for RVO or CSR, such as:

        Evidence of new optic disc cupping. Evidence of new visual field defects. Intraocular
        pressure greater than 21mm Hg as measured by tonography.

          -  Presence of active gastrointestinal disease or other condition that will interfere
             significantly with the absorption, distribution, metabolism or excretion of drugs.
             Previous colectomy is acceptable.

          -  Subjects with brain metastases are excluded, unless:

        All known lesions must be previously treated with surgery or stereotactic radiosurgery,
        and Brain lesion(s), if present, must be confirmed stable (i.e., no increase in lesion
        size) for greater than or equal to 90 days prior to first dose of study drug(s).  This
        must be documented with two consecutive MRI or CT scans using contrast, and Asymptomatic
        with no corticosteroids requirement for greater than or equal to 30 days prior to first
        dose of study drug(s), and No enzyme-inducing anticonvulsants for greater than or equal to
        14 days prior to first dose of study drug(s).

        In addition, for subjects that had brain metastases but currently have no evidence of
        disease (NED), NED for greater than or equal to 12 weeks is required and must be confirmed
        by two consecutive MRI or CT scans (using contrast) separated by greater than or equal to
        6 weeks, prior to randomization. Enrollment of a subject with brain metastases who meet
        the above criteria requires approval of a GSK Medical Monitor.

          -  Psychological, familial, sociological or geographical conditions that do not permit
             compliance with the protocol.

          -  History or evidence of cardiovascular risk including any of the following:

        LVEF less than LLN A QT interval corrected for heart rate using the Bazett's formula
        (QTcB) greater than or equal to 480 msec; History or evidence of current clinically
        significant uncontrolled arrhythmias. Exception:  Subjects with controlled atrial
        fibrillation for greater than 30 days prior to randomization are eligible.

        History of acute coronary syndromes (including myocardial infarction and unstable angina),
        coronary angioplasty, or stenting within 6 months prior to randomization.

        History or evidence of current greater than or equal to Class II congestive heart failure
        as defined by New York Heart Association (NYHA).

        Treatment refractory hypertension defined as a blood pressure of systolic greater than 140
        mmHg and/or diastolic greater than 90 mm Hg which cannot be controlled by
        anti-hypertensive therapy; Subjects with intra-cardiac defibrillators or permanent
        pacemakers; Known cardiac metastases;

          -  Unstable pulmonary embolism, deep vein thrombosis, or other significant
             arterial/venous thromboembolic event less than or equal to 30 days before
             randomization.  If on anticoagulation, subject must be on stable therapeutic dose
             prior to randomization.

          -  Subjects with a history of pneumonitis or interstitial lung disease (ILD).

          -  Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
             chemically related to the study drug(s) or their excipients.

          -  Pregnant or lactating female.

          -  Unwillingness or inability to follow the procedures outlined in the protocol.

          -  Uncontrolled diabetes or other medical condition that may interfere with assessment
             of toxicity.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7600</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris cedex 12</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aichi</city>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chiba</city>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 15, 2014</lastchanged_date>
  <firstreceived_date>December 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BRAF mutation</keyword>
  <keyword>expansion cohorts</keyword>
  <keyword>safety</keyword>
  <keyword>Advanced Colorectal Cancer</keyword>
  <keyword>KRAS wild-type</keyword>
  <keyword>Dose escalation</keyword>
  <keyword>combination dosing</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
